Shattuck Labs, Inc. (STTK)
NASDAQ:STTK
Want to see STTK full AI Analyst Report?
Top Page
Shattuck Labs
(NASDAQ:STTK)
Select Model
Select Model
Rating:53Neutral
Price Target:
$8.00
▲(6.24% Upside)
Action:ReiteratedDate:04/21/26
The score is held back primarily by weak financial performance (minimal/volatile revenue, large losses, and ongoing cash burn). Technicals are supportive with a strong uptrend, but overbought signals add near-term risk. Valuation is constrained by negative earnings, while the ATM offering modestly helps funding flexibility but carries dilution risk.
Positive Factors
Proprietary ARC platform & pipeline
Shattuck’s ARC platform creates a durable technical moat by enabling engineered, multi-functional biologics targeting immune checkpoints. As a platform with clinical and preclinical assets, it supports multiple development shots on goal and long-term value creation if trials advance.
Negative Factors
Significant cash burn
Material negative operating and free cash flow indicate persistent cash burn that must be covered by external financing. Ongoing negative cash generation elevates dilution risk, forces management to prioritize fundraising over operations, and creates execution risk if capital access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ARC platform & pipeline
Shattuck’s ARC platform creates a durable technical moat by enabling engineered, multi-functional biologics targeting immune checkpoints. As a platform with clinical and preclinical assets, it supports multiple development shots on goal and long-term value creation if trials advance.
Read all positive factors
Shattuck Labs (STTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$585.00M
Dividend YieldN/A
Average Volume (3M)510.13K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth-82.52%
EPS Growth47.92%
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.12
Shares Outstanding75,581,790
10 Day Avg. Volume433,238
30 Day Avg. Volume510,133
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue317.20
Enterprise Value/Gross Profit-179.11
Enterprise Value/Ebitda-6.82
Forecast
1Y Price Target
$12.40Price Target Upside64.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Shattuck Labs Business Overview & Revenue Model
Company Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for t...
How the Company Makes Money
null...
Shattuck Labs Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
74
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.00M | 5.72M | 1.66M | 652.00K | 30.02M |
| Gross Profit | -2.69M | 5.72M | -2.38M | 652.00K | 28.64M |
| EBITDA | -47.84M | -76.74M | -87.92M | -100.26M | -43.89M |
| Net Income | -48.81M | -75.41M | -87.30M | -101.94M | -44.97M |
Balance Sheet | |||||
| Total Assets | 91.03M | 91.05M | 159.56M | 205.32M | 298.58M |
| Cash, Cash Equivalents and Short-Term Investments | 78.06M | 72.99M | 130.63M | 161.28M | 268.80M |
| Total Debt | 1.58M | 3.41M | 4.20M | 4.90M | 0.00 |
| Total Liabilities | 8.64M | 11.42M | 14.86M | 29.17M | 26.80M |
| Stockholders Equity | 82.39M | 79.63M | 144.71M | 176.16M | 271.79M |
Cash Flow | |||||
| Free Cash Flow | -39.95M | -60.57M | -81.64M | -106.11M | -65.04M |
| Operating Cash Flow | -39.88M | -60.52M | -81.23M | -94.50M | -57.12M |
| Investing Cash Flow | -7.89M | -8.51M | 110.86M | 49.44M | -10.44M |
| Financing Cash Flow | 44.57M | 787.00K | 48.62M | 171.00K | 1.93M |
Shattuck Labs Technical Analysis
Positive
7.53
Price Trends
5.49
Positive
4.51
Positive
3.01
Positive
Market Momentum
0.49
Negative
71.00
Negative
77.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Positive. The current price of 7.53 is above the 20-day moving average (MA) of 6.64, above the 50-day MA of 5.49, and above the 200-day MA of 3.01, indicating a bullish trend. The MACD of 0.49 indicates Negative momentum. The RSI at 71.00 is Negative, neither overbought nor oversold. The STOCH value of 77.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STTK.
Shattuck Labs Risk Analysis
Shattuck Labs disclosed 55 risk factors in its most recent earnings report. Shattuck Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shattuck Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $88.16M | -2.64 | -291.42% | ― | ― | 54.52% | |
53 Neutral | $585.00M | -7.52 | -65.03% | ― | -82.52% | 47.92% | |
53 Neutral | $74.00M | -1.19 | -57.23% | ― | ― | 16.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $48.05M | -21.38 | -311.80% | ― | 589.88% | 69.82% |
* Healthcare Sector Average
STTK
Shattuck Labs
7.72
6.92
865.00%
PYPD
PolyPid
4.58
2.06
81.75%
COEP
Coeptis Therapeutics Holdings
15.20
6.23
69.45%
XLO
Xilio Therapeutics
8.18
-2.81
-25.58%
ACRV
Acrivon Therapeutics, Inc.
1.88
0.33
21.29%
Shattuck Labs Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Shattuck Labs Sets Earlier Date for 2026 Annual Meeting
Neutral
Feb 5, 2026
On February 5, 2026, Shattuck Labs’ board set May 28, 2026 as the date for its 2026 annual meeting of stockholders, a shift to a significantly earlier meeting date than the prior year. As a result of this scheduling change, the company revis...
Business Operations and StrategyPrivate Placements and Financing
Shattuck Labs Launches $75 Million At-The-Market Offering
Positive
Jan 22, 2026
On January 22, 2026, Shattuck Labs, Inc. entered into a sales agreement with Leerink Partners LLC to offer and sell from time to time up to $75 million of its common stock through an at-the-market equity program registered under an effective shelf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.